[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv-infections":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,64,98,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":38,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":5},"100614592","evaluation-of-the-q-pad-hrhpv-test-system-for-identifying-precancer-100614592",false,"NCT07281599","Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer","EQUIP","Inclusion Criteria:\n\n* You are 25 years old or older and have an intact cervix.\n* You were referred for a colposcopy after an abnormal Pap or HPV screen.\n* Your periods come regularly-about every 21-35 days.\n* You own a smartphone, have an email address, and can read the Qvin app instructions in English.\n* You are willing to sign the consent form (electronically).\n* You agree to use a condom for any vaginal intercourse or shared penetrative toy use from Q-Pad collection until the colposcopy visit if engaging with a new sexual partner during this period.\n\nExclusion Criteria:\n\n* You are pregnant or think you might be.\n* You are unwilling or unable to use the two Q-Pads and mail them back (mailing costs are covered).\n* You had treatment for cervical pre-cancer (CIN2+)-such as LEEP, cone, or ablation-within the last 12 months.\n* You have already joined this study or are in another cervical-screening \u002F HPV study right now.",true,"FEMALE","25 Years",{"count":20,"type":21},450,"ESTIMATED","INTERVENTIONAL",[24],"NA","The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing.\n\nThe same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.",[27,28,29,30,31,32,33,34,35,36,37],"HPV Infection","HPV 16 Infection","High Risk HPV","Cervical Cancer Screening","Cervical Cancer Cin Grade","Cervical Cancer (Early Detection)","HPV","HPV (Human Papillomavirus)-Associated","HPV DNA","HPV Infections","Screening Test",[39,40,41,42,43,44,45,46,47,48,33,49,50,51],"Q-Pad","Self-sampling","Self-collection","self-collect","cervical cancer screening","menstural blood","Sexually Transmitted Diseases, Viral","Sexually Transmitted Diseases","Genital Diseases","Papillomavirus Infections","high risk HPV","pap smear","at-home collection","RECRUITING","2026-01-29",{"date":55,"type":56},"2026-02-02","ACTUAL",{"date":58,"type":56},"2025-12-01",{"date":60,"type":21},"2027-03",{"name":62,"class":63},"Qurasense","INDUSTRY",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100567781","phase-1-tolerance-and-effectiveness-of-c14-on-hpv-infection-100567781","NCT06672653","Tolerance and Effectiveness of C14 on HPV Infection","PREPAP Study: Tolerance and Effectiveness of the Monoterpenoid Zinc Tetra-ascorbo-camphorate (C14) on the Genital Load of Oncogenic HPV (HR-HPV) and Precancerous Cervical Lesions: Research With Direct Individual Benefit","PREPAP","Inclusion Criteria:\n\n* sexually-active women\n* aged at least 30 years old\n* who will give their informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant\n* breastfeeding and post-partum women will not be accepted in the study.\n* previous cervical surgery, medical history of any severe diseases, intake or application of other antivirals\n* known or suspected allergic or adverse response to the investigational product or its components\n* women who are unable to follow the study protocol.","30 Years","65 Years",{"count":75,"type":21},66,[77,78],"PHASE1","PHASE2","The zinc monoterpenoid tetra-ascorbo-camphorate possesses broad-spectrum anti-viral properties in vitro, particularly against HIV, HSV and HPV. Its C14 formulation could be a promising candidate for in vivo clinical evaluation as a potential microbicide or therapeutic drug.\n\nThe aim of this clinical trial is to determine whether C14 is effective in reducing the genital viral load of HR-HPV and in treating low-grade dysplastic lesions of the cervix. It will also determine the tolerability of C14. The main questions to be answered by the clinical trial are as follows:\n\nDoes C14 reduce the genital HR-HPV viral load in participants with persistent HR-HPV infections? What medical problems do participants experience when taking C14? Researchers will compare C14 to a placebo (a similar substance that contains no drug) to see if C14 is effective in reducing genital C14 viral load and in treating low-grade dysplastic lesions of the cervix.\n\nParticipants will\n\nreceive four monthly treatments (5ml of C14 dissolved in distilled water administered twice daily \\[morning and evening\\] for seven days via vaginal syringe during the follicular phase) of C14 or placebo for 4 months and visit the clinic once every 2 weeks for examinations and tests. They will keep a diary of their symptoms and the number of times they keep the hospital appointment.",[81,36,82,83,84,85,86],"HPV-induced Cancers","HIV","Cervical Cancers","Trial","C14","Monoterpenoid Zinc Tetra-ascorbo-camphorate","NOT_YET_RECRUITING","2024-11-01",{"date":90,"type":56},"2024-11-04",{"date":92,"type":21},"2024-11-15",{"date":94,"type":21},"2025-07-15",{"name":96,"class":63},"MGB Pharma",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":16,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":118,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100467790","immune-persistence-after-the-whole-vaccination-shcedule-with-recombination-quadrivalent-hpv-vaccine-100467790","NCT05371353","Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine","Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial","Inclusion Criteria:\n\n* Subjects who participated in the phase III clinical trial of non inferior efficacy of HPV tetravalent vaccine of Yangchun Center for Disease Control and Prevention (protocol No.: 4-HPV-3001), completed three doses of HPV quadrivalent vaccine and provided blood sample at months 7; Or subjects who have participated in the bridging study of HPV quadrivalent vaccine of Mianyang Center for Disease Control and Prevention (scheme No.: 4-HPV-3002), completed the whole vaccine schedule at month 0，2，6, and provided blood sample at months 7;\n* The subjects aged 9 to 17 years old at Mianyang site and their legal guardian should provide legal indentification; the subjects aged over 18 years old should provide legal indentification;\n* The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form;\n* Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements.\n\nExclusion Criteria:\n\n* Enrolling or plan to enroll in other clinical trials (drugs or vaccines) (except that the observational clinical study and the subjects at Mianyang site are still in the post exemption safety follow-up stage of the 4-HPV-3002 trial);\n* Suffering from thrombocytopenia or any coagulation dysfunction that can be a contraindication to blood collection (such as coagulation factor deficiency, coagulation diseases, platelet abnormalities, etc.);\n* According to the investigator's judgment, the subject has any condition may interfere with process of evaluation of immune persistence.","9 Years","45 Years",{"count":108,"type":21},600,"OBSERVATIONAL","To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.",[36,112,113,114,115,116,117],"Cervical Cancer Stage IIa","Vaginal Cancer","Genital Wart","CIN1","CIN2","CIN3",[119,120,121],"Human papillomavirus","vaccine","Cervical Cancer","2024-04-15",{"date":124,"type":56},"2024-04-17",{"date":126,"type":56},"2022-05-14",{"date":128,"type":21},"2027-05",{"name":130,"class":63},"Shanghai Bovax Biotechnology Co., Ltd.",2,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":16,"sex":17,"minAge":105,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":97},"100441393","phase-3-immunogenicity-and-safety-of-quadrivalent-hpv-vaccine-in-healthy-chinese-female-subjects-aged-9-to-19-years-100441393","NCT05027776","Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial","Inclusion Criteria:\n\n1. Healthy Chinese females aged 9 to 26 years; Provide legal identification;\n2. The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form;\n3. Had a negative urine pregnancy test on the day of enrollment, among the subjects of childbearing age; Not in the duration of breast-feeding and no birth plan within 7 months; According to the investigator's judgment that there is no possibility of pregnancy at that time: subjects have taken effective contraception, or asexual life after the last menstrual period, or use IUD, or had undergone ligation; subjects agree to continue take effective contraception such as taking OCS and condom use;\n4. No fever symptoms on the day of enrollment (aged\\> 14 years old, axillary temperature\\\u003C37.3°C; aged ≤ 14 years old, axillary temperature\\\u003C37.5°C );\n5. Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements;\n\nExclusion Criteria:\n\n1. Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this study period or have enrolled in HPV vaccine clinical trials;\n2. Enrolling or plan to enroll in other clinical trials (drug or vaccine);\n3. History of positive test to HPV, history of cervical cancer (e.g. abnormal screening test results, abnormal cervical biopsy results, including CIN, LSIL, and cervical cancer) or history of pelvic radiotherapyherpes;\n4. History of diseases related to HPV infection (e.g. genital warts, VIN, VaIN, and related cancers) or history of STDs, including syphilis, gonorrhea, genital herpes, Mycoplasma genitalium, Lymphgranuloma Venereum, granuloma inguinale, etc.;\n5. Known allergy to any vaccine components or history of severe allergic diseases requiring treatment, including shock, laryngeal edema, urticarial, Henoch-Schonlein purpura, Arthus reaction, etc.;\n6. Had primary or acquired immunodeficiency such as HIV, SLE, JRA, etc;\n7. History of epilepsy and convulsions (except fever convulsions in children under 5 years of age);\n8. Subjects with existing infectious diseases such as TB, viral hepatitis, and\u002For HIV infection; or existing liver or kidney conditions, CVDs, and malignancy;\n9. Untreated\u002Funcontrolled hypertension before vaccination (aged 9 to 17 years: systolic BP≥120mmHg and\u002For diastolic BP≥80mmHg; aged more than 18 years: Systolic BP≥140mmHg and\u002For diastolic BP ≥90mmHg);\n10. With prohibitive contraindications such as Thrombocytopenia or coagulopathy;\n11. Asplenic, functionally asplenic, or splenectomy caused by any condition;\n12. Received immunosuppressive treatment within one month before study such as long-term glucocorticoid use(≥2mg per kg per day, lasted more than two wks), or plan to receive such treatment from month 0 to month 7；\n13. Receipt of immune globulin or blood-related products within 3 months; or plan to receive such products during this study period（month 0 to month 7）;\n14. Within 3 days prior to vaccination, have an acute disease or are in the acute attack of a chronic disease or have used antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, loratadine, ceti Rizine, etc.);\n15. Receipt of inactivated, RNA, and recombinant vaccines within 14 days, live vaccines within 28 days;\n16. Subjects with existing mental illness, History of mental illness, or Family History;\n17. According to the investigator's judgment, the subject has any condition may interfere with process of evaluation or participating in this study cannot guarantee the object's maximum benefit.","26 Years",{"count":141,"type":21},1348,[143],"PHASE3","This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years",[36,112,113,114,115,116,117],[119,120,121],{"date":124,"type":56},{"date":149,"type":56},"2021-09-15",{"date":151,"type":21},"2026-09-29",{"name":130,"class":63}]